Cannabis Law Report

MARCH 30, 2022

Senate Bill 253: The Cannabidiol and Marihuana Research Expansion Act provides the office of US Attorney General, rather than the US Drug Enforcement Administration, the discretion to license scientists to engage in clinical trials involving the use of cannabis by human subjects. Additional information is available from NORML here.

Legislation 95

Legislation Clinical Trials DEA Access 95

Cannabis Law Report

OCTOBER 12, 2021

Leveraging its deep expertise in nucleic acid-based technologies, the Company has also established safeCircle™, a pooled COVID-19 testing program that is grounded in the Company’s EUA-authorized Linea™ COVID-19 Assay Kit. Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Programs 52

Programs Clinical Trials Research and Development Therapy 52

Cannabis Law Report

OCTOBER 2, 2021

MAPS PBC catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics. The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times.

Clinical Trials 52

Clinical Trials Research and Development Compliance Compliance 52

Cannabis Law Report

AUGUST 3, 2021

Cybin was well funded before this financing, and this new funding now further extends the runway for our drug programs, discovery pipeline and IP portfolio, and provides additional flexibility to support potential M&A opportunities. Actual results and future events could differ materially from those anticipated in such information.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Cannabis Law Report

DECEMBER 9, 2021

The Company believes it has produced a sufficient supply of cGMP DMT to complete its planned Phase 1 and Phase 2 clinical trials. as medical consultants to the Company’s DMT stroke clinical research program. Simister have extensive backgrounds in stroke management as well as clinical care and stroke research.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. Excellent communication skills, especially in communicating regulations, contingencies, and technical information.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Cannabis Law Report

AUGUST 17, 2021

Orphan drug designation provides certain benefits, including market exclusivity upon regulatory approval, if received, exemption of FDA application fees and tax credits for qualified clinical trials. For more information visit www.marinuspharma.com. Conference Call and Webcast Details. Forward-Looking Statements.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JULY 24, 2021

“At Mydecine, we are excited to expand our drug development program to include the improvement of entactogenic compounds,” said Rob Roscow, Chief Scientific Officer. For more information, please contact: Media Contacts. For further information about Mydecine Innovations Group, Inc., Anne Donohoe / Nick Opich. myco@kcsa.com.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

JULY 28, 2021

MAPS Public Benefit Corporation (MAPS PBC) catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics prioritizing public benefit above profit. More information about the organization is available at [link].

Clinical Trials 105

Clinical Trials Research and Development Data Environment 105

The Cannigma

OCTOBER 14, 2022

San Marino medical marijuana program. The program does not include cannabis flower or home grow. The program does not include cannabis flower or home grow. This medication is provided at no cost to residents of the country. Is CBD legal in San Marino? CBD has not been specifically legalized in San Marino.

Law 56

Law Clinical Trials Research and Development Recreational 56

Cannabis Law Report

MARCH 1, 2022

Work with the Lead of Regulatory Affairs and the atai Development Team, and with moderate/minimal supervision, with select project teams within subsidiary organizations to develop and oversee program specific regulatory, clinical and development strategies. 5 years of hands-on regulatory experience.

Clinical Trials 52

Clinical Trials Environment Pharmaceutical Programs 52

Cannabis Law Report

JUNE 30, 2021

s (CSE: MXT) (OTC: MXTTF) SHAMAN and YMI programs apply machine learning to high-resolution health records to better diagnose mental health disorders. In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials.

Treatment 52

Treatment Clinical Trials Research and Development Data 52

Cannabis Law Report

OCTOBER 13, 2021

Filed in support of the Company’s CYB004 pre-clinical development program, the PCT filing serves to increase the Company’s library of drug delivery modalities directed to optimal delivery of psychedelics and further strengthens Cybin’s growing IP portfolio. Vigorous scientific research and clinical trials are needed.

Clinical Trials 52

Clinical Trials Research and Development Treatment Conditions 52

SpeedWeed

SEPTEMBER 17, 2021

Data collected from MAPS-sponsored Phase 3 clinical trials suggests that MDMA-assisted therapy appears promising in the treatment of TBI. Wesana outlined five key goals: Gain expertise and information to design psychedelic-assisted therapy programs for TBI and improve the Wesana timeline and path to market for its treatments.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Cannabis Law Report

JANUARY 12, 2022

“We can now concentrate all our energies on advancing our plant-inspired, biopharmaceutical research and development programs into human clinical trials.” Andrea Small-Howard, President and Chief Science Officer of Gb Sciences. ” Gb Sciences’ intellectual property portfolio includes five U.S. 31, 2021.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

MAY 10, 2022

Medicinal cannabis products such as capsules, creams, oils, lozenges, sprays and granulated flowers were approved for prescription 159,665 times between the start of Australia’s medicinal cannabis program in February 2016 and September 2021, research led by the University of Sydney’s Lambert Initiative for Cannabinoid Therapeutics shows.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Cannabis Law Report

OCTOBER 2, 2021

Work with the Lead of Regulatory Affairs and the atai Development Team, and with moderate/minimal supervision, with select project teams within subsidiary organizations to develop and oversee program specific regulatory, clinical and development strategies. 5 years of hands-on regulatory experience.

Clinical Trials 52

Clinical Trials Environment Pharmaceutical Programs 52

Cannabis Law Report

DECEMBER 26, 2021

In furtherance of its program, the Company filed US Provisional Patent Application No. “Entheon is proud to be making significant strides in its Entheon IQ™ program,” says Timothy Ko, Chief Executive Officer of Entheon. EBRX-101 on Track to Submit Regulatory Package for Human DMT Clinical Trial.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

MMJ Recs

APRIL 1, 2024

Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders. Exploring CBD for Medical Use As interest in CBD grows, researchers are continuously exploring its potential applications in the medical field.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

JANUARY 19, 2022

GMP psilocybin previously manufactured by Psygen personnel in collaboration with a licensed dealer using Psygen’s methods has already been used in clinical trials for development of therapeutic products. Cautionary Statements Regarding Forward-Looking Information. About Psygen.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Conditions 52

Cannabis Law Report

JULY 29, 2021

Tetra Bio-Pharma ( TSX: TBP ) ( OTCQB: TBPMF ) ( FRA:JAM1 ) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. For more information visit: www.tetrabiopharma.com.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., For more information visit www.marinuspharma.com.

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

JUNE 4, 2021

Clinical trial information: NCT03276572 ( [link] ). The full ASCO meeting program is available at: www.asco.org. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law. About AIkido Pharma Inc.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

JUNE 8, 2021

This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Patients 92

Patients Research and Development Clinical Trials Chronic Pain 92

Cannabis Law Report

JANUARY 6, 2022

Anderson will be responsible for Anebulo’s global investor relations and public relations programs. He serves as the primary spokesperson and point of contact with the analyst and investment community and is also responsible for the timely dissemination of information and data to these important stakeholders.

Pharmaceutical 52

Pharmaceutical Clinical Trials Cannabinoids Programs 52

Cannabis Law Report

JULY 26, 2021

Tyle brings over 35 years of experience in the pharmaceutical industry, with over 37 years in senior executive leadership positions encompassing research and development, clinical development, manufacturing, regulatory, business development and operations as well as roles as a board director and scientific advisory board member. Karam Takhar.

Research and Development 105

Research and Development Clinical Trials Pharmaceutical Cannabinoids 105

Cannabis Law Report

JANUARY 12, 2022

According to a recent report released by the Psychedelic Science Funders Collaborative, “Oregon’s psilocybin therapy program provides a high-quality model for psychedelic healing in a non-prescription context that could be replicated in other states.”

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

SEPTEMBER 2, 2021

– Company’s safeCircle™ Testing Program to Monitor for COVID-19 Among On-Campus Unvaccinated Populations –. Under the Contract, ADCL will deploy safeCircle™, its high-throughput, pooled COVID-19 testing program, to provide cost-effective COVID-19 testing. Visit adnas.com for more information. STONY BROOK, N.Y.–(BUSINESS

Clinical Trials 99

Clinical Trials Research and Development Therapy Collective 99

Cannabis Law Report

AUGUST 25, 2021

“Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 111

Clinical Trials Research and Development Therapy Conditions 111

Cannabis Law Report

FEBRUARY 10, 2022

Psilocybin’s therapeutic benefits are so promising that Denver, Colorado became the first city to decriminalize psilocybin in May 2019, and in 2020, Oregon passed Measure 109, which paved the road for a program allowing for legal manufacture, delivery, and administration of psilocybin to clients at supervised, licensed facilities in the state.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Veriheal

AUGUST 31, 2020

Program between St. About Sinibaldo: Sinibaldo is an aspiring healthcare professional and a biomedical researcher in the Medical Scientist Training Program (M.D./Ph.D.) About Nishtha: Nishtha is pursuing neurology to become a physician-scientist in honor of her grandmother Nani who suffered from Alzheimer’s.

Research and Development 117

Research and Development Education Agriculture Patients 117

SpeedWeed

AUGUST 16, 2021

We couldn’t be more thrilled to host Dr. Sisley at Cannabis Conference 2021 as our Day 2 keynote,” said Cannabis Conference Programming Director Cassie Neiden Tomaselli. “Dr. More information about Cannabis Conference, including sessions, speakers, exhibitors and FAQs, can be found at www.CannabisConference.com. 25 from 11 a.m. –

Media 52

Media Clinical Trials DEA Hemp 52

Veriheal

MAY 26, 2022

The ORR, an ongoing online survey study, collects self-reported health information to be analyzed by Johns Hopkins for published research papers. In addition to the large uptick in registrants, we saw an even larger influx of new visitors to our site, enabling them to learn more about our research program.”.

Advocacy 98

Advocacy Patients Clinical Trials Education 98

Otherside Farms

JANUARY 25, 2019

Norman Smith: “Since I am the only successful patient in the clinical trial, to take away something that’s been part of a successful regimen does not make any sense” In September 2010, Smith became eligible for a liver transplant, but after testing positive for marijuana in February he was removed from the transplant list.

Patients 76

Patients Clinical Trials Marijuana Policy 76

Cannabis Law Report

JANUARY 13, 2020

In particular, we see significant market opportunity for nabiximols in several indications in the US and will be progressing multiple late stage clinical programs in 2020.”. Commence clinical program to expand future label to include spasticity associated with Spinal Cord Injury. Commence clinical program in PTSD.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

OCTOBER 17, 2019

The introduction of these protocols will take the form of clinical trials and research that will include the usage of specific strains of cannabis that aid in chronic pain and cancer treatments. Tree of Knowledge will be introducing chronic pain management protocols and research into the Caribbean market.

Clinical Trials 40

Clinical Trials Research and Development Chronic Pain CBD 40

Cannabis Law Report

NOVEMBER 9, 2021

As an institution dedicated to diagnosing and treating serious blood diseases and with the ability to pursue investigational medicines from development to manufacture and clinical trial for patients who have exhausted all approved treatment options, having a cost-effective and rapid production chain is integral to ÚHKT’s mission.

Clinical Trials 52

Clinical Trials Research and Development Therapy Supply Chain 52